SHANGHAI YIZHONG PHARMACEUTICAL CO., LTD.

Shanghai Yizhong Pharmaceutical Co., Ltd.

688091

CNE1000050F4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 13/06/2024 am IST			5-day change	1st Jan Change
25.8 ^CNY	+0.90%		+0.74%	-47.59%

30/04	Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises	RE
29/04	Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shanghai Yizhong Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 1.007745 billion.

September 03, 2021 at 09:30 am IST

Shanghai Yizhong Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 1.007745 billion.

Security Name: A Shares
Security Type: Common Stock
Securities Offered: 26,450,000
PriceRange: CNY 38.1

Latest news about Shanghai Yizhong Pharmaceutical Co., Ltd.

Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises	30/04	RE
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02	CI
Yizhong Pharmaceutical Starts Construction of Paclitaxel Polymer Micelles Production Facility; Shares Down 3%	05/02	MT
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Yizhong Pharmaceutical's Plant Passes Good Manufacturing Practice Inspection of Shanghai's Drug Regulator	27/23/27	MT
Shanghai Yizhong Pharmaceutical Co., Ltd.(XSSC:688091) added to S&P Global BMI Index	18/23/18	CI
Certain A Shares of Shanghai Yizhong Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 9-SEP-2023.	09/23/09	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	17/23/17	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Chinese Oncology Body Includes Yizhong Pharma's Drug in Non-Small Cell Lung Cancer Treatment Guidelines	24/23/24	MT
Yizhong Pharma Gets Nod to Trial Lung Cancer Drug in China	17/23/17	MT
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	19/22/19	CI
Shanghai Yizhong Pharmaceutical Co., Ltd.(SHSE:688091) added to Shanghai Stock Exchange A Share Index	09/22/09	CI
Shanghai Yizhong Pharmaceutical Co., Ltd.(SHSE:688091) added to Shanghai Stock Exchange Composite Index	09/22/09	CI
Certain A Shares of Shanghai Yizhong Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 9-SEP-2022.	09/22/09	CI
Shanghai Yizhong Pharmaceutical’s CFO Steps Down; Successor Named	18/22/18	MT
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	17/22/17	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	23/22/23	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 1.007745 billion.	03/21/03	CI
Shanghai Yizhong Pharmaceutical Co., Ltd. has filed an IPO.	09/20/09	CI

Chart Shanghai Yizhong Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Yizhong Pharmaceutical Co., Ltd.

More charts

Company Profile

Shanghai Yizhong Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development and industrialization of new and improved anti-tumor drugs. The Company's main products include paclitaxel micelles, docetaxel micelles and cabazitaxel micelles. Paclitaxel micelles are products under development that have been submitted for registration and marketing applications, and their indications are non-small cell lung cancer. Docetaxel micelles and cabazitaxel micelles are products under development in the pre-clinical research stage.

Sector

Pharmaceuticals

Calendar

16/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI YIZHONG PHARMACEUTICAL CO., LTD.	-47.59%	727M
KYOWA KIRIN CO. LTD.	+13.33%	9.15B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+49.51%	4.65B
SK BIOPHARMACEUTICALS CO., LTD.	-20.82%	4.58B
YUHAN CORPORATION	+8.58%	4.07B
INDIVIOR PLC	+7.59%	2.24B
BETTA PHARMACEUTICALS CO., LTD.	-25.68%	2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+10.42%	2.03B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-41.65%	1.82B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B